Olivia Belbin

Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis.

Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.

Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.

Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility.

Erratum to: Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility.

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies.

Synaptic phosphorylated α-synuclein in dementia with Lewy bodies.

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease.

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Nanoscale structure of amyloid-β plaques in Alzheimer's disease.

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis.

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.

Genetic variants in glutamate-, Aβ-, and tau-related pathways determine polygenic risk for Alzheimer's disease.

Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome.

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.

Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia.

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone.

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.

Fluid markers of synapse degeneration in synucleinopathies.

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.

Myelin loss in C9orf72 hexanucleotide expansion carriers.